Chung Shiu-Dong, Chueh Shih-Chieh, Lai Ming-Kuen, Huang Chao-Yuan, Pu Yeong-Shiau, Yu Hong-Jeng, Huang Kuo-How
Department of Urology, Far-Eastern Memorial Hospital, Ban-Ciao, Taipei County, Taiwan.
J Endourol. 2007 Jun;21(6):595-9. doi: 10.1089/end.2006.9948.
To evaluate the efficacy and long-term outcome of hand-assisted laparoscopic radical nephroureterectomy (HALNU) in treating upper urinary-tract transitional-cell carcinoma (UT-TCC).
We analyzed the data from 39 patients who underwent HALNU in our institution between January 1999 and December 2002 for urothelial carcinoma of the ureter or kidney. Preoperative and perioperative data were collected retrospectively by reviewing medical records. The oncologic outcomes, including bladder recurrence-free survival, cancer-specific survival, and overall survival, were compared with those of 36 contemporary patients undergoing conventional open radical nephroureterectomy (ONU). The median follow-up was 48 months (range 6 2 months) in the HALNU group and 59.5 months in the ONU group (range 8 8 months). Patients ages, sex, body mass index, pathologic parameters, and American Society of Anesthesiologists (ASA) classification showed no significant difference between the groups.
The HALNU group had statistically less blood loss (183 mL v 422 mL; P = 0.02). The average hospital stay and dose of narcotic analgesics were significantly less in the HALNU group. The complication rates were similar (12.8% for HALNU and 8.3% for ONU; P = 0.53). The 5-year bladder recurrence-free survival, cancer-specific survival, and overall survival were similar in the two groups.
The HALNU is a less-invasive technique with 5-year bladder recurrence-free survival, cancer-specific survival, and overall survival rates similar to those of ONU for patients with UT-TCC.
评估手辅助腹腔镜根治性肾输尿管切除术(HALNU)治疗上尿路移行细胞癌(UT-TCC)的疗效和长期预后。
我们分析了1999年1月至2002年12月间在我院接受HALNU治疗输尿管或肾盂尿路上皮癌的39例患者的数据。通过查阅病历回顾性收集术前和围手术期数据。将包括无膀胱复发生存率、癌症特异性生存率和总生存率在内的肿瘤学预后与36例同期接受传统开放性根治性肾输尿管切除术(ONU)的患者进行比较。HALNU组的中位随访时间为48个月(范围6至2个月),ONU组为59.5个月(范围8至8个月)。两组患者的年龄、性别、体重指数、病理参数和美国麻醉医师协会(ASA)分级无显著差异。
HALNU组术中失血在统计学上更少(183 mL对422 mL;P = 0.02)。HALNU组的平均住院时间和麻醉性镇痛药用量显著更少。两组的并发症发生率相似(HALNU组为12.8%,ONU组为8.3%;P = 0.53)。两组的5年无膀胱复发生存率、癌症特异性生存率和总生存率相似。
对于UT-TCC患者,HALNU是一种侵入性较小的技术,其5年无膀胱复发生存率、癌症特异性生存率和总生存率与ONU相似。